2431. Evaluation of Clinical Outcomes in Bacteremia Due to AmpC β-Lactamase Producing Organisms Stratified by Treatment

作者
Travis J Carlson,Kady Phe,Hannah Palmer Russo
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:5 (suppl_1): S727-S727
标识
DOI:10.1093/ofid/ofy210.2084
摘要

Enterobacteriaceae and Pseudomonas aeruginosa are common bloodstream pathogens with variable AmpC β-lactamase (AmpC) incidence. The clinical utility of treatment with non-carbapenem/cefepime options remains unclear. The objective of this study was to compare the clinical outcomes for patients receiving a carbapenem or cefepime (CC) and alternative therapy (AT) for bacteremia caused by organisms known to produce AmpC. Hospitalized adults with a confirmed mono-microbial bacteremia admitted from June 2016 to December 2017 were included. Patients were stratified by definitive therapy (DT) with CC or AT. The AT group was treated with fluoroquinolones, third-generation cephalosporins, piperacillin–tazobactam, aztreonam, or tobramycin. The primary outcome was in-hospital mortality. Secondary outcomes included treatment failure, microbiological failure, hospital length of stay (LOS), and intensive care unit LOS. Multiple regression analysis was used to adjust for potential confounding variables. Of 68 patients meeting eligibility criteria, 46% received CC for DT. Enterobacteriaceae were isolated in 45% of patients in the CC group. In-hospital mortality was 32% and 3% (P = 0.0017) in the CC and AT groups, respectively. Source control, APACHE II score on the date of index culture, and immune status did not differ between groups. Definitive CC therapy was independently associated with mortality (odds ratio, 15.17; 95% confidence interval, 1.69–135.76; P = 0.0150). Only 6 (9%) patients received AT as empiric and DT. Those who received definitive AT received a median of 5 days (interquartile range, 3–9 days) of CC prior to being switched to AT. While most patients received empiric CC, definitive treatment with CC was found to be an independent predictor of in-hospital mortality. These findings suggest that AT may be a de-escalation treatment strategy for clinicians to consider. However, these results should be confirmed in a larger population. All authors: No reported disclosures.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4399完成签到,获得积分10
1秒前
liukang172完成签到,获得积分10
1秒前
清见的心完成签到,获得积分10
1秒前
qinyinping完成签到,获得积分10
1秒前
www完成签到,获得积分10
1秒前
眼睛大的小熊猫完成签到,获得积分10
2秒前
缥缈的绿兰完成签到,获得积分10
2秒前
阿申爱乐的应助被369ninja采纳,获得30
3秒前
李健的应助被fogsea采纳,获得10
3秒前
fzw完成签到 ,获得积分10
3秒前
3秒前
Chris完成签到,获得积分10
3秒前
粉鼻子发布了新的文献求助10
4秒前
捞鱼发布了新的文献求助10
4秒前
rosy完成签到,获得积分10
5秒前
无限迎蕾完成签到,获得积分10
5秒前
朵朵完成签到,获得积分10
6秒前
赘婿的应助被氢锂钠钾铷铯钫采纳,获得10
6秒前
Wendy完成签到,获得积分10
6秒前
xushanfeng完成签到,获得积分10
6秒前
李薇完成签到,获得积分10
6秒前
7秒前
刘先生完成签到 ,获得积分10
7秒前
泡芙大王完成签到,获得积分10
7秒前
jr发布了新的文献求助10
7秒前
今后的应助被77采纳,获得10
8秒前
北陌完成签到 ,获得积分10
8秒前
fanligang完成签到,获得积分10
8秒前
zilicai的应助被张临秋采纳,获得60
8秒前
TaoJ完成签到,获得积分10
8秒前
arsenal完成签到 ,获得积分10
8秒前
傻傻的妙之完成签到,获得积分10
8秒前
lsh完成签到,获得积分10
8秒前
重要山水完成签到,获得积分10
8秒前
8秒前
Dreamchaser完成签到,获得积分10
9秒前
纳兰嫣然完成签到,获得积分10
9秒前
SY完成签到,获得积分10
9秒前
大饼哥完成签到,获得积分10
10秒前
Andrew_Y完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039